Avia Logo

Compare Products


Jump to:
Categories
Solutions
Description
Compatibility Level
Clients
Use cases
EHR integrations
Client types
Differentiators
Keywords
Media
Company details
Jump to:
Categories
Solutions
Description
Compatibility Level
Clients
Use cases
EHR integrations
Client types
Differentiators
Keywords
Media
Company details
DiagMMR
DiagMMR

0 review

Grail
Grail

0 review

Categories

Solutions

Description

Product Description:

DiagMMR is designed to be a predictive diagnostic tool that enables preventive follow-up and counselling for affected mutation carriers who are at high risk for developing Lynch syndrome related cancers.

While current Lynch syndrome diagnosis relies heavily on tumor studies, the quantitative DiagMMR method allows carrier diagnosis based on a minimally invasive tissue sample before the person has developed any cancer, without the knowledge and details of an inherited mutation.

The inherent challenges to variant interpretation in genetic testing can be avoided and the conclusive and actionable results removes the burden of uncertainty from both the patients and the treating medical professionals.

About LS CancerDiag:
LS CancerDiag Ltd is committed to reducing cancer mortality rates with a low-cost, simple diagnostic method that detects an inherited cancer-causing condition prior to cancer. Their vision is to see DiagMMR™ as a new global testing standard in LS diagnostics. Lynch syndrome is the main cause of hereditary colorectal cancers and it also causes a broad spectrum of other tumors. With a significant proportion of the world’s population carrying the Lynch syndrome mutation, there are potentially tens of millions under a severe risk for being affected by LS. Their groundbreaking DiagMMR™ assay is an easy functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary Non­Polyposis Colorectal Cancer; HNPCC). Their mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome by delivering predictive and accurate results with a fast, unique and cost-efficient method globally.
Product Description:
GRAIL is a life sciences company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection. The company has secured over $1B in venture funding led by ARCH Venture Partners and including Amazon, Bezos Expeditions, Bill Gates, Bristol-Myers Squibb, Celgene, GV, Illumina, Johnson & Johnson Innovation, Merck, McKesson Ventures, Sutter Hill Ventures, Tencent, Varian Medical Systems, and other financial partners. If you’re ready to join a mission with meaning, bring your passion to GRAIL. Together we will make history in the fight against cancer.
About Grail:
GRAIL is a life sciences company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection. The company has secured over $1B in venture funding led by ARCH Venture Partners and including Amazon, Bezos Expeditions, Bill Gates, Bristol-Myers Squibb, Celgene, GV, Illumina, Johnson & Johnson Innovation, Merck, McKesson Ventures, Sutter Hill Ventures, Tencent, Varian Medical Systems, and other financial partners. If you’re ready to join a mission with meaning, bring your passion to GRAIL. Together we will make history in the fight against cancer.

Compatibility level

Select which hospital or health system you work at and see a personalized compatibility level.

Clients

Select which hospital or health system you work at and see the client list

Use Cases

Description:

LYNCH SYNDROME

1 in 279 people have Lynch syndrome, i.e. inherited mismatch repair (MMR) deficiency, making it the most common cause of hereditary cancers.

INHERITED DEFECT

Lynch syndrome (LS) is inherited with 50% probability within affected families. Each single year, more than 2 million new cancer cases should be tested for LS.

INDIVIDUAL RISK

Individuals with inherited MMR deficiency have an up to 80% risk of developing cancer and at a significantly younger age than the general population.

INNOVATIVE SOLUTION

DiagMMR is a simple and accurate test to reliably detect MMR deficiency, supporting the early detection of Lynch syndrome, enabling preventive care and helping save lives.

Pediatric use cases:

None provided

Users:

Not specified

Description:

None provided

Pediatric use cases:

None provided

Users:

None provided

EHR Integrations

Integrations:

None provided

EMR Integration & Relevant Hardware:

None provided

EMRs Supported:

None provided

Hardware Compatibility:

None provided

Integrations:

None provided

EMR Integration & Relevant Hardware:

None provided

EMRs Supported:

None provided

Hardware Compatibility:

None provided

Client Types

None provided
None provided

Differentiators

Differentiators vs EHR Functionality:

None provided

Differentiators vs Competitors:

None provided

Differentiators vs EHR Functionality:

None provided

Differentiators vs Competitors:

None provided

Keywords

Images

No images provided

No images provided

Videos

1 of 1

edit-media

No videos provided

Downloads

No content provided

No content provided

Alternatives

Company Details

Founded in 2013

team illustration
Share your product comparison with your collegues.

Need help narrowing down products?

Add more criteria to see your compatibility level for every vendor. It only takes a few minutes, just create a free account to get started.
back to top